VANCOUVER, BC--A $350,000 proteomics research grant awarded to Kinetek Pharmaceuticals by the National Research Council will be used for bioinformatics developments, the company said. "To date, the defining problem facing proteomics has been the development of bioinformatics techniques to isolate key data from vast amounts of irrelevant information," said Andr Archimbaud, president and CEO of Kinetek. "This collaboration with leading proteomics researchers at the National Research Council addresses this issue." The grant will involve close collaboration between Kinetek and the research council's Institute for Marine Biosciences in Halifax, NS, which houses a genomics program including a DNA sequencing facility and the Canadian Bioinformatics Resource, managed by Christoph Sensen.
Robert Boyd, acting director of the institute said, "An integrated approach that capitalizes on DNA sequencing, functional genomics, proteomics, and bioinformatics offers a unique advantage for understanding molecular biology." He added, "Such an integrated platform is an objective of future developments."
Kinetek's functional proteomics program, which it calls Kineomics, integrates functional proteomics and bioinformatics to identify those protein kinases that show aberrant enzymatic activity in the disease state. By using cell-based assays and disease models the program determines which protein kinases identified by proteomics cause disease.